# Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

> **NCT00751478** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALO-01
- **DRUG:** MSIR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00751478
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751478, "Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00751478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*